Erika Hamilton, MD, FASCO (@ErikaHamilton9) ranks #5 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 87 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: SERENA-6, OPTIMA (UK), BRIDGET. CMS Open Payments lists $43,302 in 2025 general payments.
At a Glance
- 16 posts naming a trial in 2026
- 13 trials discussed by name
- Breast Cancer: US #5, Global #6 · 87 physicians engaged
- Leading physician voice: #2 of 39 physicians on SERENA-6; #3 of 23 physicians on PANKU-Breast01
- Presented at SABCS 2025, ASCO 2026 in 2026
- CMS Open Payments lists $43,302 in 2025 general payments.
This Month
What Erika Hamilton, MD, FASCO has posted in the last 30 days. Updated November 10, 2026.
Fantastic data by @drsarahsam in #BRIDGET showing the activity of #tucatinib in pts with 🧠 mets....used in combo w/ standard therapies..building upon what we saw in HER2CLIMB. ⬆️ unmet need! #ESMO26 #ESMOAmbassadors @OncoAlert https://t.co/1Rw2hsE4dh
@BGarmezy presents #JNJ6143 AR #RIPTAC in mCRPC at #ESMO26 🔑only 3% pts discontinue/ 3% reduce at 50mg! 🏃♂️ 66% pts remain on 📉 PSA50 achieved in 83% ARv7+ pts w/ evaluable CTCs ✅ 88% DCR, 69% cORR @SarahCannonDocs https://t.co/yExjBrH1rN
#PANKUBreast01 Ph III results for iza bren (bispecific EGFR/HER3 ADC) vs TPC chemo, in previously treated HR +/HER- MBC 🔹mPFS: 4.0 vs. 8.1 mo, HR 0.41 🔹 ORR: 20% vs 40% 🔹 DoR: 4.2 vs. 6.9 mo 🔹 ILD: only 1.1% & all grade 1/2 #ESMO26 #ESMOAmbassadors https://t.co/ikHLXiLHX1
TALENT- neoadj T-DXd in HR+/HER2-low #bcsm RCB0/1: 🔹 T-DXd alone: 16% 🔹 T-DXd + anastrozole: 17% 🔹 T-DXd → TC chemo: 17% *no pCRs w/out 8 cycles Despite high ORR ~66%, pCR LOW! We know w/ HR+ we don't get high pCRs rates, but still disappointing #ESMO26 #ESMOAmbassadors https://t.co/smlF5DmAAt
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Erika Hamilton, MD, FASCO
Physicians who reposted Erika Hamilton, MD, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #5 | #6 | 87 | 175 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Erika Hamilton, MD, FASCO presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- SABCS 2025 · General session (GS1-01)HER2CLIMB-05 primary results: adding tucatinib to trastuzumab + pertuzumab maintenance in HER2+ advanced breast cancer
- ASCO 2026 · PresentationHER2CLIMB-05: additional efficacy and safety results
What Colleagues Are Saying About Erika Hamilton, MD, FASCO
2026 posts by fellow physicians that mention @ErikaHamilton9, quoted word for word.
A few studies that we touched on during our #ESMOBreast26 highlights 🗣️ w/ @ErikaHamilton9 (a good starting point just before we walk into #ASCO26)! ✅ #VERITAC2 ✅ #PREcoopERA ✅ #PHERGain ✅ #SATEEN & #BRE354 ✅ #TROPIONBreast02 #OncTwitter #bcsm #MedTwitter @myESMO https://t.co/72PZ2FWtzY https://t.co/DzmahXTNzf
JUST IN: @FDA approves Vepdegestrant (heterobifunctional protein degrader) for ER+/HER2– Advanced Breast Cancer with an ESR1 Mutation. Trial led by @ErikaHamilton9 and presented @ASCO #ASCO25 Link: https://t.co/23AqFJ9hpL https://t.co/rgU6Wrbd4Z
HER2CLIMB-05 subgroup analysis @ErikaHamilton9 Adding tucatinib to trastuzumab/pertuzumab maintenance therapy improved PFS across all major subgroups of HER2+ metastatic breast cancer, including HR-positive and HR-negative disease, patients with or without brain metastases, and both de novo and recurrent disease. Safety was consistent across subgroups, supporting tucatinib as a potential new maintenance option. #ASCO26
Absolutely incredible, 11 approvals in half of a year! Tucatinib is now approved in front line maintainence for HER2+ MBC a win for patients! Kudos to @ErikaHamilton9 and team for their study of HER2CLIMB05! @SCRIOncology @SarahCannonDocs https://t.co/jy0utGuo1i
Beautiful presentation by @ErikaHamilton9 on HER2CLIMB-05! Subset analysis of pts with HR+ dz by ET use highlights how critical it is to give ET to our HR+ HER2+ pts @OncoAlert #ASCO26 https://t.co/UzSUO7fGhV
Trials Erika Hamilton, MD, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| SERENA-6 | 5 | #2 of 39 | May 27, 2026 |
| OPTIMA (UK) | 2 | #5 of 24 | May 30, 2026 |
| BRIDGET | 1 | #7 of 17 | Oct 26, 2026 |
| JNJ6143 | 1 | #12 of 16 | Oct 24, 2026 |
| PANKU-Breast01 | 1 | #3 of 23 | Oct 23, 2026 |
| TALENT (TRIO-US B-12) | 1 | #11 of 23 | Oct 23, 2026 |
| ASCENT03 | 1 | #5 of 19 | Jun 24, 2026 |
| ASCENT-04 | 1 | #10 of 24 | Jun 24, 2026 |
| EVERA | 1 | #12 of 30 | May 31, 2026 |
| lidERA | 1 | #10 of 23 | May 30, 2026 |
| NATALEE | 1 | #21 of 46 | May 30, 2026 |
| VERITAC-2 (vepdegestrant) | 1 | #6 of 18 | May 1, 2026 |
| VERITAC-2 | 1 | #3 of 10 | May 1, 2026 |
Erika Hamilton, MD, FASCO on SERENA-6
Additional data coming #ASCO26 re: #SERENA6 👀 #bcsm https://t.co/oxKWxpfZFn
Prof. Bidard presents info re: emergence of #ESR1m on #SERENA6. Numerically highest during 12-48 months of 1L AI and CDK4/6 20% found in 1st year of therapy #ESMOBreast26 https://t.co/A7AoR4cT4x
This is really the takeaway from today's #ODAC vote 6-3 against recommending approval of #camizestrant at this time based on #SERENA6. We don't know yet what the benefit of an early switch in the absence of radiographic PD is long term. PFS2 as designed here doesn't answer. https://t.co/lXz1l73B1K
Erika Hamilton, MD, FASCO on OPTIMA (UK)
#OPTIMA looked at Prosigna ability to predict chemo benefit in higher nodal burden ER+ #bcsm 🎙️pts with ROR ≤60 could avoid chemo, incl. premeno >40 receiving OFS AND higher N+ disease ***limitations: 63% of pts <5 yrs f/u, no one <40 yrs #ASCO26 https://t.co/C4pi3T5WBO
Agree- this is the takeaway. Previously, the 🙋♀️ has been how much of the premeno chemo benefit was chemo itself and how much was chemo-induced ovarian failure? #OPTIMA mandated OFS, so eliminated this variable and suggests that the OFS was the majority of benefit. #ASCO26 https://t.co/j7Du1IHv1V
Erika Hamilton, MD, FASCO on BRIDGET
Fantastic data by @drsarahsam in #BRIDGET showing the activity of #tucatinib in pts with 🧠 mets....used in combo w/ standard therapies..building upon what we saw in HER2CLIMB. ⬆️ unmet need! #ESMO26 #ESMOAmbassadors @OncoAlert https://t.co/1Rw2hsE4dh
Erika Hamilton, MD, FASCO on JNJ6143
@BGarmezy presents #JNJ6143 AR #RIPTAC in mCRPC at #ESMO26 🔑only 3% pts discontinue/ 3% reduce at 50mg! 🏃♂️ 66% pts remain on 📉 PSA50 achieved in 83% ARv7+ pts w/ evaluable CTCs ✅ 88% DCR, 69% cORR @SarahCannonDocs https://t.co/yExjBrH1rN
Erika Hamilton, MD, FASCO on PANKU-Breast01
#PANKUBreast01 Ph III results for iza bren (bispecific EGFR/HER3 ADC) vs TPC chemo, in previously treated HR +/HER- MBC 🔹mPFS: 4.0 vs. 8.1 mo, HR 0.41 🔹 ORR: 20% vs 40% 🔹 DoR: 4.2 vs. 6.9 mo 🔹 ILD: only 1.1% & all grade 1/2 #ESMO26 #ESMOAmbassadors https://t.co/ikHLXiLHX1
Erika Hamilton, MD, FASCO on TALENT (TRIO-US B-12)
TALENT- neoadj T-DXd in HR+/HER2-low #bcsm RCB0/1: 🔹 T-DXd alone: 16% 🔹 T-DXd + anastrozole: 17% 🔹 T-DXd → TC chemo: 17% *no pCRs w/out 8 cycles Despite high ORR ~66%, pCR LOW! We know w/ HR+ we don't get high pCRs rates, but still disappointing #ESMO26 #ESMOAmbassadors https://t.co/smlF5DmAAt
Erika Hamilton, MD, FASCO on ASCENT03
#ASCENT03 and #ASCENT04 approval today by @US_FDA for #bcsm #sacituzumabgovitecan 1st line with or without pembro This makes 7️⃣ FDA #bcsm approvals since May 1st, I think they deserve some rest over there. Great work, FDA! https://t.co/jSQ5Vpks3F
Erika Hamilton, MD, FASCO on ASCENT-04
#ASCENT03 and #ASCENT04 approval today by @US_FDA for #bcsm #sacituzumabgovitecan 1st line with or without pembro This makes 7️⃣ FDA #bcsm approvals since May 1st, I think they deserve some rest over there. Great work, FDA! https://t.co/jSQ5Vpks3F
Erika Hamilton, MD, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Fantastic summary slide of metastatic #bcsm #ADC landscape by @BarbaraPistill2 in her #ESMO26 discussion #ESMOAmbassadors @OncoAlert What do we need next??? 📍novel payloads 📍novel targets 📍data on sequencing https://t.co/AlbwYGRHP0
#datoDXd FDA approved 1st line TNBC among pts who are not a candidate for immunotherapy Not 1️⃣, not 2️⃣, but now 3️⃣ approvals in #bcsm this month! #vepdegestrant #TDxd neoadj/adj #datodxD 1st L https://t.co/FXeEAWVkqE
#DB05 update on #ILD with T-DXd 10% ILD 🫁 , 2 cases fatal Radiation pneumonitis ☢️ (RP) incidence ~ 30% Having ILD did not ⬆️ chance of RP 📌No diff in ILD 🫁 based on sequential or concurrent radiotherapy ☢️ Moderate renal dysfunction ⬆️ risk ILD #ASCO26 https://t.co/m20jvpCnUC
Ok, #bcsm, what do we make of exemestane looking worse than anastrazole by 4.9% in GIM3 FATA? Fluke? Otherwise, no difference between upfront or switch strategies. #ESMO26 #ESMOAmbassadors https://t.co/noFZyCgacr
#FOURLIGHT1 CDK4 atirmociclib Fulv + atirmo vs TPC (fulvestrant or exe/evero) post ET+ CDK4/6 in ER+ #bcsm PFS improved 6.6 to 9.4 mos, HR 0.60 #ESMO26 #ESMOAmbassadors @OncoAlert **1st line trial and curative trials coming!*** https://t.co/fCu7aFNbUq
Industry Payments
CMS Open Payments · 2025 general payments
$43,302 across 117 payments